Vicriviroc Is a Novel, Potent CCR5 Inhibitor With Outstanding Pharmaceutic, Pharmacokinetic and PharmaCodynamic (PK/PD) Properties

The CCR5 chemokine receptor is a promising target for antiretroviral therapy because of its role as a coreceptor for HIV entry and propagation of infection. Vicriviroc, a small molecule CCR5 inhibitor being studied in clinical trials, has shown potent in vitro activity against HIV (IC90<13 nM). In addition, the pharmaceutic and PK/PD properties of vicriviroc appear to distinguish it from other compounds in clinical development.